Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways

Current Opinion in Pharmacology

Volumn 5, Issue 2 SPEC. ISS., 2005, Pages 135-142

  Caglayan, Evren ^a,b   Blaschke, Florian ^b   Takata, Yasunori ^b   Hsueh, Willa A ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOKINETIC HORMONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; ROSIGLITAZONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIUM LESION; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 15044365745     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.01.008     Document Type: Review

References (81)

1. H.M. Lakka D.E. Laaksonen T.A. Lakka L.K. Niskanen E. Kumpusalo J. Tuomilehto J.T. Salonen The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709-2716
2. E.S. Ford W.H. Giles A.H. Mokdad Increasing prevalence of the metabolic syndrome among US adults Diabetes Care 27 2004 2444-2449
3. Third report of the National Cholesterol Education Program Expert Panel on Detection: Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). [URL: http://www.nhlbi.nih.gov/ guidelines/cholesterol/index.htm]
4. P. Dandona A. Aljada P. Mohanty H. Ghanim W. Hamouda E. Assian S. Ahmad Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86 2001 3257-3265
5. K. Cusi K. Maezono A. Osman M. Pendergrass M.E. Patti T. Pratipanawatr R.A. DeFronzo C.R. Kahn L.J. Mandarino Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle J Clin Invest 105 2000 311-320
6. G. Zeng F.H. Nystrom L.V. Ravichandran L.N. Cong M. Kirby H. Mostowski M.J. Quon Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells Circulation 101 2000 1539-1545
7. C. Banfi P. Eriksson G. Giandomenico L. Mussoni L. Sironi A. Hamsten E. Tremoli Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: Insights into the signaling pathway Diabetes 50 2001 1522-1530
8. M. Montagnani I. Golovchenko I. Kim G.Y. Koh M.L. Goalstone A.N. Mundhekar M. Johansen D.F. Kucik M.J. Quon B. Draznin Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells J Biol Chem 277 2002 1794-1799
9. S.B. Williams J.A. Cusco M.A. Roddy M.T. Johnstone M.A. Creager Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus J Am Coll Cardiol 27 1996 567-574
10. J.F. Oram K.E. Bornfeldt Direct effects of long-chain non-esterified fatty acids on vascular cells and their relevance to macrovascular complications of diabetes Front Biosci 9 2004 1240-1253
11. K.L. Wyne Free fatty acids and type 2 diabetes mellitus Am J Med 115 Suppl 8A 2003 29S-36S
12. J.C. Fruchart M.C. Nierman E.S. Stroes J.J. Kastelein P. Duriez New risk factors for atherosclerosis and patient risk assessment Circulation 109 2004 III15-III19
13. H. Masuzaki H. Yamamoto C.J. Kenyon J.K. Elmquist N.M. Morton J.M. Paterson H. Shinyama M.G. Sharp S. Fleming J.J. Mullins et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J Clin Invest 112 2003 83-90
14. G. Nickenig Should angiotensin II receptor blockers and statins be combined? Circulation 110 2004 1013-1020
15. U. Kintscher S. Wakino S. Kim E. Fleck W.A. Hsueh R.E. Law Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes Hypertension 37 2001 587-593
16. P.E. Tummala X.L. Chen C.L. Sundell J.B. Laursen C.P. Hammes R.W. Alexander D.G. Harrison R.M. Medford Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis Circulation 100 1999 1223-1229
17. X.L. Chen P.E. Tummala M.T. Olbrych R.W. Alexander R.M. Medford Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells Circ Res 83 1998 952-959
18. D.E. Vaughan S.A. Lazos K. Tong Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis J Clin Invest 95 1995 995-1001
19. B. Williams Angiotensin II and the pathophysiology of cardiovascular remodeling Am J Cardiol 87 2001 10C-17C
20. V.J. Dzau Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis Hypertension 37 2001 1047-1052
21. D. Bruemmer A.R. Collins G. Noh W. Wang M. Territo S. Arias-Magallona M.C. Fishbein F. Blaschke U. Kintscher K. Graf et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice J Clin Invest 112 2003 1318-1331
22. S. Yusuf P. Sleight J. Pogue J. Bosch R. Davies G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145-153
23. R. Carmena P. Duriez J.C. Fruchart Atherogenic lipoprotein particles in atherosclerosis Circulation 109 2004 III2-III7
24. R.S. Gray D.C. Robbins W. Wang J.L. Yeh R.R. Fabsitz L.D. Cowan T.K. Welty E.T. Lee R.M. Krauss B.V. Howard Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study Arterioscler Thromb Vasc Biol 17 1997 2713-2720
25. J. Vakkilainen S. Makimattila A. Seppala-Lindroos S. Vehkavaara S. Lahdenpera P.H. Groop M.R. Taskinen H. Yki-Jarvinen Endothelial dysfunction in men with small LDL particles Circulation 102 2000 716-721
26. C. Skoglund-Andersson R. Tang M.G. Bond U. de Faire A. Hamsten F. Karpe LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men Arterioscler Thromb Vasc Biol 19 1999 2422-2430
27. G. Walldius I. Jungner I. Holme A.H. Aastveit W. Kolar E. Steiner High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study Lancet 358 2001 2026-2033
28. A.D. Sniderman T. Scantlebury K. Cianflone Hypertriglyceridemic hyperapob: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Ann Intern Med 135 2001 447-459
29. C.J. Lyon R.E. Law W.A. Hsueh Minireview: Adiposity, inflammation, and atherogenesis Endocrinology 144 2003 2195-2200
30. A.M. Thogersen J.H. Jansson K. Boman T.K. Nilsson L. Weinehall F. Huhtasaari G. Hallmans High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 1998 2241-2247
31. P.Y. Scarabin M.F. Aillaud P. Amouyel A. Evans G. Luc J. Ferrieres D. Arveiler I. Juhan-Vague Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction Thromb Haemost 80 1998 749-756
32. G.J. Blake P.M. Ridker C-reactive protein and other inflammatory risk markers in acute coronary syndromes J Am Coll Cardiol 41 2003 37S-42S
33. P.M. Ridker High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention Am J Cardiol 92 2003 17K-22K
34. G. Yang D.C. Merrill M.W. Thompson J.E. Robillard C.D. Sigmund Functional expression of the human angiotensinogen gene in transgenic mice J Biol Chem 269 1994 32497-32502
35. P. Ziccardi F. Nappo G. Giugliano K. Esposito R. Marfella M. Cioffi F. D'Andrea A.M. Molinari D. Giugliano Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year Circulation 105 2002 804-809
36. P. Dandona R. Weinstock K. Thusu E. Abdel-Rahman A. Aljada T. Wadden Tumor necrosis factor-alpha in sera of obese patients: Fall with weight loss J Clin Endocrinol Metab 83 1998 2907-2910
37. T. Yamauchi J. Kamon H. Waki Y. Terauchi N. Kubota K. Hara Y. Mori T. Ide K. Murakami N. Tsuboyama-Kasaoka et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat Med 7 2001 941-946
38. T. Yamauchi J. Kamon Y. Ito A. Tsuchida T. Yokomizo S. Kita T. Sugiyama M. Miyagishi K. Hara M. Tsunoda et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects Nature 423 2003 762-769
39. C. Weyer T. Funahashi S. Tanaka K. Hotta Y. Matsuzawa R.E. Pratley P.A. Tataranni Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia J Clin Endocrinol Metab 86 2001 1930-1935
40. R.S. Lindsay T. Funahashi R.L. Hanson Y. Matsuzawa S. Tanaka P.A. Tataranni W.C. Knowler J. Krakoff Adiponectin and development of type 2 diabetes in the Pima Indian population Lancet 360 2002 57-58
41. K.C. Tan A. Xu W.S. Chow M.C. Lam V.H. Ai S.C. Tam K.S. Lam Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation J Clin Endocrinol Metab 89 2004 765-769
42. M. Kumada S. Kihara S. Sumitsuji T. Kawamoto S. Matsumoto N. Ouchi Y. Arita Y. Okamoto I. Shimomura H. Hiraoka et al. Association of hypoadiponectinemia with coronary artery disease in men Arterioscler Thromb Vasc Biol 23 2003 85-89
43. N. Ouchi S. Kihara T. Funahashi T. Nakamura M. Nishida M. Kumada Y. Okamoto K. Ohashi H. Nagaretani K. Kishida et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue Circulation 107 2003 671-674
44. N. Ouchi S. Kihara Y. Arita K. Maeda H. Kuriyama Y. Okamoto K. Hotta M. Nishida M. Takahashi T. Nakamura et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin Circulation 100 1999 2473-2476
45. N. Ouchi S. Kihara Y. Arita M. Nishida A. Matsuyama Y. Okamoto M. Ishigami H. Kuriyama K. Kishida H. Nishizawa et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages Circulation 103 2001 1057-1063
46. Y. Arita S. Kihara N. Ouchi K. Maeda H. Kuriyama Y. Okamoto M. Kumada K. Hotta M. Nishida M. Takahashi et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell Circulation 105 2002 2893-2898
47. H. Chen M. Montagnani T. Funahashi I. Shimomura M.J. Quon Adiponectin stimulates production of nitric oxide in vascular endothelial cells J Biol Chem 278 2003 45021-45026
48. T. Yamauchi J. Kamon H. Waki Y. Imai N. Shimozawa K. Hioki S. Uchida Y. Ito K. Takakuwa J. Matsui et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis J Biol Chem 278 2003 2461-2468
49. Y. Okamoto S. Kihara N. Ouchi M. Nishida Y. Arita M. Kumada K. Ohashi N. Sakai I. Shimomura H. Kobayashi et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice Circulation 106 2002 2767-2770
50. N. Maeda I. Shimomura K. Kishida H. Nishizawa M. Matsuda H. Nagaretani N. Furuyama H. Kondo M. Takahashi Y. Arita et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat Med 8 2002 731-737
51. V. Schachinger A.M. Zeiher Prognostic implications of endothelial dysfunction: Does it mean anything? Coron Artery Dis 12 2001 435-443
52. J.A. Suwaidi S. Hamasaki S.T. Higano R.A. Nishimura D.R. Holmes Jr. A. Lerman Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction Circulation 101 2000 948-954
53. M. Shimabukuro N. Higa T. Asahi Y. Oshiro N. Takasu T. Tagawa S. Ueda I. Shimomura T. Funahashi Y. Matsuzawa Hypoadiponectinemia is closely linked to endothelial dysfunction in man J Clin Endocrinol Metab 88 2003 3236-3240
54. G. Manjunath H. Tighiouart H. Ibrahim B. MacLeod D.N. Salem J.L. Griffith J. Coresh A.S. Levey M.J. Sarnak Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J Am Coll Cardiol 41 2003 47-55
55. H. Miettinen S.M. Haffner S. Lehto T. Ronnemaa K. Pyorala M. Laakso Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects Stroke 27 1996 2033-2039
56. E.M. Stuveling S.J. Bakker H.L. Hillege J.G. Burgerhof P.E. de Jong R.O. Gans D. de Zeeuw C-reactive protein modifies the relationship between blood pressure and microalbuminuria Hypertension 43 2004 791-796
57. G. Berton R. Cordiano R. Palmieri R. De Toni G.L. Guarnieri P. Palatini Albumin excretion in diabetic patients in the setting of acute myocardial infarction: Association with 3-year mortality Diabetologia 47 2004 1511-1518
58. P. Gaede P. Vedel N. Larsen G.V. Jensen H.H. Parving O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383-393
59. K. Esposito R. Marfella M. Ciotola C. Di Palo F. Giugliano G. Giugliano M. D'Armiento F. D'Andrea D. Giugliano Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial JAMA 292 2004 1440-1446
60. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
61. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39-III43
62. A. Keech D. Colquhoun J. Best A. Kirby R.J. Simes D. Hunt W. Hague E. Beller M. Arulchelvam J. Baker et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial Diabetes Care 26 2003 2713-2721
63. S.M. Grundy J.I. Cleeman C.N. Merz H.B. Brewer Jr. L.T. Clark D.B. Hunninghake R.C. Pasternak S.C. Smith Jr. N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227-239
64. UK HDL-C Consensus Group: Role of fibrates in reducing coronary risk: A UK Consensus. Curr Med Res Opin 2004, 20:241-247.
65. N. Marx G.K. Sukhova T. Collins P. Libby J. Plutzky PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 99 1999 3125-3131
66. P. Delerive F. Martin-Nizard G. Chinetti F. Trottein J.C. Fruchart J. Najib P. Duriez B. Staels Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway Circ Res 85 1999 394-402
67. K.J. Mather S. Verma T.J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J Am Coll Cardiol 37 2001 1344-1350
68. M.J. Quinones M. Hernandez-Pampaloni H. Schelbert I. Bulnes-Enriquez X. Jimenez G. Hernandez R. De La Rosa Y. Chon H. Yang S.B. Nicholas et al. Coronary vasomotor abnormalities in insulin-resistant individuals Ann Intern Med 140 2004 700-708
69. M. Iwaki M. Matsuda N. Maeda T. Funahashi Y. Matsuzawa M. Makishima I. Shimomura Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors Diabetes 52 2003 1655-1663
70. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106-1118
71. S. Wakino R.E. Law W.A. Hsueh Vascular protective effects by activation of nuclear receptor PPARgamma J Diabetes Complications 16 2002 46-49
72. T. Claudel M.D. Leibowitz C. Fievet A. Tailleux B. Wagner J.J. Repa G. Torpier J.M. Lobaccaro J.R. Paterniti D.J. Mangelsdorf et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor Proc Natl Acad Sci USA 98 2001 2610-2615
73. A.R. Collins W.P. Meehan U. Kintscher S. Jackson S. Wakino G. Noh W. Palinski W.A. Hsueh R.E. Law Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 21 2001 365-371
74. Z. Chen S. Ishibashi S. Perrey J. Osuga T. Gotoda T. Kitamine Y. Tamura H. Okazaki N. Yahagi Y. Iizuka et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: Pleiotropic effects on CD36 expression and HDL Arterioscler Thromb Vasc Biol 21 2001 372-377
75. A.C. Li K.K. Brown M.J. Silvestre T.M. Willson W. Palinski C.K. Glass Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 2000 523-531
76. M. Schupp J. Janke R. Clasen T. Unger U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2004 2054-2057
77. A. Niklason T. Hedner L. Niskanen J. Lanke Development of diabetes is retarded by ACE inhibition in hypertensive patients - A subanalysis of the Captopril Prevention Project (CAPPP) J Hypertens 22 2004 645-652
78. K.H. Berecek A. Farag G. Bahtiyar J. Rothman S.I. McFarlane The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: Focus on the diabetic patient Curr Hypertens Rep 6 2004 212-214
79. B. Dahlof R.B. Devereux S.E. Kjeldsen S. Julius G. Beevers U. de Faire F. Fyhrquist H. Ibsen K. Kristiansson O. Lederballe-Pedersen et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 2002 995-1003
80. M.A. Weber S. Julius S.E. Kjeldsen H.R. Brunner S. Ekman L. Hansson T. Hua J.H. Laragh G.T. McInnes L. Mitchell et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 363 2004 2049-2051
81. S. Yusuf J.B. Ostergren H. Gerstein Impact of the angiotensin receptor blocker Candesartan in preventing diabetes in patients with heart failure JACC 43 2004 801